News
CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
Australia's CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other re
